Trial Profile

A Phase 1b/2a Open Label Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Budoprutug in Adult Participants With Sys-temic Lupus Erythematosus (SLE)

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I/II

Latest Information Update: 21 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Oct 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.
15 Oct 2024 According to Climb Bio media release, company anticipates Initiation of Phase 1b clinical trial in SLE planned for the first half of 2025
15 Oct 2024 According to Climb Bio media release, company will present data from phase 1b part of this trial at the American Society of Nephrology Kidney Week 2024, which will take place in San Diego, CA from October 24, 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com